Emtriva

Emtriva is a brand name of emtricitabine, approved by the FDA in the following formulation(s):

EMTRIVA (emtricitabine - capsule; oral)

• 
  Manufacturer: GILEAD
  
  Approval date: July 2, 2003
  
  Strength(s): 200MG ^[RLD]

EMTRIVA (emtricitabine - solution; oral)

• 
  Manufacturer: GILEAD
  
  Approval date: September 28, 2005
  
  Strength(s): 10MG/ML ^[RLD]

Has a generic version of Emtriva been approved?

No. There is currently no therapeutically equivalent version of Emtriva available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Emtriva. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Method for the synthesis, compositions and use of 2'-deoxy-5-fluoro-3'-thiacytidine and related compounds
  Patent 5,814,639
  Issued: September 29, 1998
  Inventor(s): Liotta; Dennis C. & Schinazi; Raymond F. & Choi; Woo-Baeg
  Assignee(s): Emory University
  The present invention relates to a method of preparing the antiviral compounds 2'-deoxy-5-fluoro-3'thiacytidine (FTC) and various prodrug analogues of FTC from inexpensive precursors with the option of introducing functionality as needed; methods of using these compounds, particularly in the prevention and treatment of AIDS; and the compounds themselves. This synthetic route allows the stereoselective preparation of the biologically active isomer of these compounds and related compounds.
  
  Patent expiration dates:
  
  
  • September 29, 2015
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • March 29, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
  Patent 5,914,331
  Issued: June 22, 1999
  Inventor(s): Liotta; Dennis C. & Schinazi; Raymond F. & Choi; Woo-Baeg
  Assignee(s): Emory University
  A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5' or N.sup.4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A process for the resolution of a racemic mixture of nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.
  
  Patent expiration dates:
  
  
  • July 2, 2017
    
    ✓ 
    Drug substance
  
  
  
  • January 2, 2018
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane
  Patent 6,642,245
  Issued: November 4, 2003
  Inventor(s): Dennis C.; Liotta & Raymond F.; Schinazi & Woo-Baeg; Choi
  Assignee(s): Emory University
  A method and composition for the treatment of HIV and HBV infections in humans is disclosed that includes administering an effective amount of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane, a pharmaceutically acceptable derivative thereof, including a 5′ or N4 alkylated or acylated derivative, or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier. A process for the resolution of a racemic mixture of nucleoside enantiomers is also disclosed that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers.
  
  Patent expiration dates:
  
  
  • November 4, 2020
    
    ✓ 
    Patent use: TREATMENT OF HIV INFECTION
  
  
  
  • November 4, 2020
    
    ✓ 
    Patent use: METHOD OF TREATMENT OF ADULTS INFECTED WITH HIV-1
  
  
  
  • May 4, 2021
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Method of resolution and antiviral activity of 1,3-oxathiolane nuclesoside enantiomers
  Patent 6,703,396
  Issued: March 9, 2004
  Inventor(s): Dennis C.; Liotta & Raymond F.; Schinazi & Woo-Baeg; Choi
  Assignee(s): Emory University
  A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-flurocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner.
  
  Patent expiration dates:
  
  
  • March 9, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • September 9, 2021
    
    ✓ 
    Pediatric exclusivity
  
  

See also...

• Emtriva Consumer Information (Drugs.com)
• Emtriva Consumer Information (Wolters Kluwer)
• Emtriva Solution Consumer Information (Wolters Kluwer)
• Emtriva Consumer Information (Cerner Multum)
• Emtriva Advanced Consumer Information (Micromedex)
• Emtriva AHFS DI Monographs (ASHP)
• Emtricitabine Consumer Information (Wolters Kluwer)
• Emtricitabine Solution Consumer Information (Wolters Kluwer)
• Emtricitabine Consumer Information (Cerner Multum)
• Emtricitabine Advanced Consumer Information (Micromedex)
• Emtricitabine AHFS DI Monographs (ASHP)

Oksaliplatin Medac

Oksaliplatin Medac may be available in the countries listed below.

Ingredient matches for Oksaliplatin Medac

Oxaliplatin

Oxaliplatin is reported as an ingredient of Oksaliplatin Medac in the following countries:

• Estonia


• Lithuania

International Drug Name Search